Creative Medical Files U.S. Provisional Patent to Expand Ultrasome™ Regenerative Medicine Platform

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has filed a new U.S. provisional patent application to expand the intellectual property protection of its Ultrasome™ cell-free regenerative medicine platform. The filing seeks to cover multiple aspects of the platform, including product composition, biological potency, manufacturing and quality-control methods, stability, delivery approaches, and therapeutic applications such as musculoskeletal and cartilage disorders.

This provisional patent filing builds on prior clinical data from a pilot study involving knee osteoarthritis patients. In that study, approximately 93% of participants demonstrated clinically meaningful improvements in mobility and pain, with no serious adverse events reported. These results highlight the potential therapeutic benefits of the Ultrasome™ platform.

The provisional application establishes an initial U.S. priority date for the Ultrasome-related intellectual property. However, it has not yet undergone examination by the U.S. Patent and Trademark Office (USPTO), and there is no assurance regarding the scope of future patent claims or whether the patent will ultimately be granted.

Creative Medical emphasizes that the filing does not confer any demonstrated clinical or regulatory status. Additional applications of the Ultrasome™ platform in musculoskeletal and cartilage disorders remain in research and development stages. Furthermore, the company holds an FDA Drug Master File for the platform, which supports scalability and product consistency through a single GMP-based cellular source. Nonetheless, this filing and the Drug Master File do not constitute FDA approval, clearance, or authorization of any therapeutic product.

The company’s stock performance prior to the announcement showed a decline of 7.12% over 24 hours on below-average trading volume. The provisional patent filing was made during a low-volume pre-headline session while the application remained unexamined.

Creative Medical’s strategic expansion of its intellectual property portfolio via this provisional patent filing underscores its commitment to advancing the Ultrasome™ platform. The broad scope of the filing aims to protect innovations across composition, potency, manufacturing controls, and potential therapeutic applications, positioning the company for future development in regenerative medicine.

Investors and industry observers should note that while the pilot study results are promising, further clinical trials and regulatory approvals are necessary to establish the platform’s efficacy and safety for widespread therapeutic use.

This development follows recent industry trends where companies are seeking to strengthen patent protection around exosome-based and cell-free regenerative technologies, reflecting growing interest in novel biologics for chronic conditions such as osteoarthritis and diabetes.

Creative Medical’s ongoing research and patent activities will be closely watched as the company advances its regenerative medicine pipeline and seeks to translate early clinical successes into commercial products.